Press Releases on November 5, 2019 - EIN Presswire - Press Release Distribution Service

Published on November 5, 2019 - 13:05 GMT

Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society ...

Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on November 5, 2019 - 13:05 GMT

Update in Lawsuit for Investors in Allegiant Travel Company (ALGT) shares announced by Shareholders Foundation

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ: ALGT shares. Investors who purchased shares of Allegiant Travel Company (NASDAQ: ALGT) in May 2015 or …

Distribution channels: Consumer Goods, Law ...

Published on November 5, 2019 - 13:02 GMT

Maxihost Selects NYI for New York City Edge Deployment

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Maxihost, a Brazilian provider of bare metal-based cloud infrastructure products offering high levels of automation, scalability and control, has selected NYI to launch the company’s New York City edge presence. …

Distribution channels: IT Industry, Media, Advertising & PR ...

Published on November 5, 2019 - 13:01 GMT

WindMIL Therapeutics to Present Data Demonstrating Marrow-Infiltrating Lymphocytes’ (MILs™) Superior Functionality Compared to ...

BALTIMORE and PHILADELPHIA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy, will present new data in a poster presentation on Saturday, November 9 …

Distribution channels: Culture, Society & Lifestyle, Media, Advertising & PR ...

Published on November 5, 2019 - 13:01 GMT

SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology - ...

Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo SQZ to also present additional preclinical data on company’s first oncology approach with SQZ-PBMC-HPV WATERTOWN, Mass., Nov. 05, …

Distribution channels: Culture, Society & Lifestyle, Media, Advertising & PR ...

Published on November 5, 2019 - 13:01 GMT

Forty Seven Inc. to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

MENLO PARK, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that it will host a live …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on November 5, 2019 - 13:01 GMT

Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual ...

- First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program - Additional data demonstrate potential of CD73 inhibitor CB-708 to combine with immuno-oncology and chemotherapy agents in solid tumors SOUTH SAN FRANCISCO, Calif …

Distribution channels: Media, Advertising & PR, Technology ...